Chen Yanting, Lin Leying, Sun Shanwei, Cui Kaiwang, Wu Qingrong
Rheumatology Department, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
School of Basic Medicine, Gannan Medical University, Ganzhou, Jiangxi, China.
Front Pharmacol. 2025 May 22;16:1482228. doi: 10.3389/fphar.2025.1482228. eCollection 2025.
The effectiveness of traditional Chinese medicine (TCM) in treating diabetes has been confirmed in China and globally. However, research on the use of Chinese herbal medicine (CHM) among middle-aged and elderly patients with diabetes and its associated factors is limited. This study aims to explore the prevalence of CHM use among these patients and its associated factors.
This study utilized data from the China Health and Retirement Longitudinal Study, which covers Chinese adults aged ≥45 years. A cross-sectional analysis was conducted on 3,347 participants who used CHM for diabetes treatment. Multivariate logistic regression models were employed to identify key factors (including demographic characteristics, health status, and healthcare utilization) that predict CHM use among patients with diabetes.
The prevalence of CHM use for diabetes was 10.8% among middle-aged and older Chinese patients with diabetes. Compared to patients with diabetes who did not use CHM, those who did were more likely to be older (OR = 1.31; 95% CI = 1.04, 1.65), visit TCM hospitals (OR = 1.24; 95% CI = 1.01, 1.53), engage in self-treatment (OR = 1.90; 95% CI = 1.38, 2.61), have kidney disease (OR = 1.50; 95% CI = 1.05, 2.14), and have asthma (OR = 2.19; 95% CI = 1.29, 3.70). In the combined effect analysis, patients with both kidney disease and asthma were most likely to use CHM (OR = 4.20; 95% CI = 1.93, 9.14).
The prevalence of CHM use among middle-aged and elderly Chinese patients with diabetes was relatively low, and was associated with specific health conditions and healthcare behaviors.
中药(TCM)治疗糖尿病的有效性在中国及全球均已得到证实。然而,针对中老年糖尿病患者使用中草药(CHM)情况及其相关因素的研究较为有限。本研究旨在探讨这些患者使用CHM的 prevalence 及其相关因素。
本研究利用了中国健康与养老追踪调查(China Health and Retirement Longitudinal Study)的数据,该调查涵盖了年龄≥45岁的中国成年人。对3347名使用CHM治疗糖尿病的参与者进行了横断面分析。采用多变量逻辑回归模型来识别预测糖尿病患者使用CHM的关键因素(包括人口统计学特征、健康状况和医疗保健利用情况)。
在中国中老年糖尿病患者中,使用CHM治疗糖尿病的 prevalence 为10.8%。与未使用CHM的糖尿病患者相比,使用CHM的患者年龄更大的可能性更高(OR = 1.31;95% CI = 1.04,1.65),就诊于中医医院的可能性更高(OR = 1.24;95% CI = 1.01,1.53),进行自我治疗的可能性更高(OR = 1.90;95% CI = 1.38,2.61),患有肾脏疾病的可能性更高(OR = 1.50;95% CI = 1.05,2.14),以及患有哮喘的可能性更高(OR = 2.19;95% CI = 1.29,3.70)。在联合效应分析中,同时患有肾脏疾病和哮喘的患者使用CHM的可能性最高(OR = 4.20;95% CI = 1.93,9.14)。
中国中老年糖尿病患者中使用CHM的 prevalence 相对较低,且与特定的健康状况和医疗保健行为相关。